외과용 접착제 시장 : 제품별, 성분별, 수술 방법별, 용도별, 최종사용자별 - 세계 예측(2025-2032년)

The Surgical Adhesives Market is projected to grow by USD 3.74 billion at a CAGR of 9.90% by 2032.

A strategic overview of how clinical demands, procedural shifts, and operational constraints are reshaping priorities for tissue adhesives across contemporary surgical practice

The surgical adhesives landscape is experiencing a pivotal convergence of clinical innovation, regulatory refinement, and shifting care delivery pathways that together are redefining how tissue approximation and hemostasis are achieved in modern surgery. Over the past decade, adhesive technologies have evolved from niche adjuncts to core components of procedural toolkits, driven by the push toward less invasive interventions, heightened expectations for surgical outcomes, and a growing emphasis on cost-effective perioperative resource utilization. Consequently, stakeholders across the value chain-from developers and contract manufacturers to hospital procurement teams and clinicians-are reassessing product portfolios, supply models, and the evidence base required for adoption.

This report begins by framing the clinical imperatives that are influencing adhesive selection, including surgeon preference patterns, patient safety priorities, and the increasing demand for adhesives that deliver reliable sealing with minimal tissue reaction. It then situates those imperatives within operational realities such as sterilization standards, packaging innovation, and inventory management pressures in high-throughput settings. By connecting clinical need to commercial strategy, the introduction clarifies why adhesives that balance performance, ease of use, and regulatory compliance are positioned to win in environments where productivity and outcomes are both scrutinized. As a result, leaders must integrate clinical validation, manufacturing resilience, and payer considerations into their product development and go-to-market roadmaps.

How minimally invasive procedures, biomaterials breakthroughs, evolving regulatory expectations, and supply chain reconfiguration are collectively redefining the surgical adhesives landscape

Several transformative shifts are accelerating change across the surgical adhesives ecosystem, each reshaping product development priorities and commercial pathways. First, the persistent migration toward minimally invasive surgery is amplifying demand for adhesives optimized for endoscopic delivery, rapid polymerization, and reduced thermal or mechanical trauma, thereby privileging materials science innovations that can be deployed through narrow lumens and articulated instruments. Second, an expanding emphasis on quality metrics and value-based procurement is compelling health systems to demand robust clinical evidence that links adhesive use to measurable outcomes such as reduced leak rates, shorter procedure times, or lower readmission risks.

Concurrently, advances in biomaterials are creating new classes of adhesives that combine bioresorbability with targeted adhesion profiles, enabling tissue-specific solutions for cardiovascular, orthopedic, and dermal applications. Regulatory pathways have also matured, with authorities signaling clearer expectations for clinical data and manufacturing controls, which affects time-to-market and commercialization strategy. Finally, global supply chain complexities and evolving procurement practices are prompting companies to pursue strategic partnerships, local manufacturing capabilities, and integrated service offerings that help customers manage cost and continuity of supply. Taken together, these shifts emphasize the need for cross-functional alignment between R&D, regulatory, and commercial teams to convert scientific progress into sustained market access and clinical adoption.

How tariff-induced cost pressures and trade policy uncertainty are driving supply chain resilience, supplier diversification, and production footprint reassessment across surgical adhesive supply chains

The interplay between trade policy and predictable supply chains has taken on renewed importance as manufacturers and health systems evaluate the indirect effects of tariff actions on input sourcing, pricing strategy, and supplier selection. In jurisdictions where tariff measures have been concentrated, companies have reported upward pressure on raw material and component costs, which has cascaded into procurement negotiations and inventory planning decisions. In response, many organizations have prioritized supplier diversification, stockpiling of critical inputs, and closer collaboration with logistics partners to mitigate exposure to tariff-induced volatility.

Beyond immediate cost implications, tariff dynamics influence strategic choices about production footprint and nearshoring. Firms seeking tariff resilience are weighing the trade-offs of localized manufacturing capacity versus the capital intensity of facility establishment. At the same time, procurement teams are re-evaluating long-term contracts to introduce greater flexibility for renegotiation or indexation to input cost movements. Clinically, the potential for supply interruptions has prompted stronger emphasis on qualifying multiple adhesive formulations and packaging options to ensure continuity of care. Taken together, these adjustments do not merely reflect short-term cost management; they signal a structural reorientation toward greater supply chain agility, contractual sophistication, and scenario planning that together reduce operational risk and preserve access to critical surgical consumables.

Precise segmentation insights that reveal where product type, composition, surgical method, application, and end-user dynamics converge to shape competitive advantage

Insightful segmentation analysis illuminates where innovation and demand intersect within the surgical adhesives arena, and this granularity is essential for prioritizing R&D and commercial initiatives. Across product types, collagen-based adhesives, cyanoacrylate adhesives, fibrin sealants, hydrocolloid adhesives, and silicone adhesives each present distinct performance profiles and clinical use cases, with some technologies better suited to rapid hemostasis while others provide durable tissue approximation or dermal compatibility. This product-level differentiation interacts closely with composition-based distinctions between biological adhesives and synthetic adhesives; biological formulations commonly emphasize biocompatibility and resorbability whereas synthetic alternatives frequently focus on tunable mechanical properties and shelf stability.

The surgical method segmentation-minimally invasive surgery versus open surgery-further shapes design priorities, as instruments and delivery modalities for less invasive approaches demand adhesives with lower viscosity, controlled curing kinetics, and compatibility with endoscopic applicators. Application areas such as cardiovascular surgery, cosmetic surgery, general surgery, and orthopedic surgery impose unique performance constraints and evidence requirements; for instance, cardiovascular use cases place heightened emphasis on hemostatic reliability and thromboresistance while cosmetic procedures prioritize aesthetic outcomes and scar minimization. End-user contexts, including ambulatory surgical centers, hospitals & clinics, and specialty care centers, influence procurement cycles, packaging preferences, and the level of training expected for clinical staff. By synthesizing these segmentation lenses, decision-makers can identify which adhesive technologies warrant prioritized investment based on clinical fit, adoption barriers, and the operational models of target customers.

Regionally differentiated adoption patterns and regulatory dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape tailored market entry and scale strategies

Regional nuances drive differentiated demand patterns, technology adoption rates, and regulatory engagement strategies that companies must navigate when planning market entry and expansion. In the Americas, robust hospital networks and a concentration of advanced surgical centers create a favorable environment for high-evidence adhesives and rapid uptake of novel delivery systems, but procurement processes can be highly decentralized and price-sensitive. Europe, the Middle East & Africa present heterogeneous regulatory regimes and clinical practices; while major European health systems often require rigorous clinical data and formal health technology assessments, other markets in the region may prioritize availability and affordability, creating distinct commercial pathways.

Asia-Pacific markets exhibit dynamic contrasts between advanced tertiary centers that rapidly adopt cutting-edge adhesives and vast community settings where cost and distribution efficiency are paramount. Furthermore, regional manufacturing capabilities and regulatory frameworks influence decisions about local production versus export models, and partnerships with regional distributors remain critical to navigating complex reimbursement and procurement landscapes. Understanding these regional differences enables companies to tailor evidence generation, pricing strategies, and go-to-market models to local expectations while preserving a coherent global product narrative that supports scale and regulatory convergence where possible.

Why clinical validation, manufacturing scale, strategic partnerships, and post-market evidence generation are decisive factors for competitive strength in surgical adhesives

Competitive positioning in the surgical adhesives sector is increasingly defined by the combination of scientific differentiation, manufacturing capability, and the ability to demonstrate meaningful clinical benefit. Organizations that emphasize clinically validated product attributes-such as rapid sealing under wet conditions, reduced inflammatory response, or compatibility with minimally invasive delivery-tend to achieve stronger traction with early adopters in tertiary centers. At the same time, scale advantages in manufacturing and distribution remain important for competing in price-sensitive channels and for supporting global regulatory submissions.

Strategic behaviors observed among leading players include targeted partnerships with clinical research centers to build the evidence base, investments in sterile fill-finish and packaging innovation to improve shelf life and usability, and selective M&A to acquire complementary technologies or expand presence in key therapeutic applications. Companies that combine a disciplined pipeline of differentiated formulations with robust quality systems and demonstrated supply continuity are better positioned to win long-term contracts with large health systems. Finally, firms that invest in clinician education and post-market surveillance generate the real-world data necessary to support product claims and inform iterative improvements, thereby reinforcing both clinical credibility and commercial defensibility.

Actionable strategic priorities for leaders to strengthen innovation pipelines, fortify supply chains, accelerate clinical adoption, and align commercial models with value-based procurement

Industry leaders seeking to capture sustainable value should adopt a multifaceted strategy that aligns product innovation with operational resilience and compelling clinical evidence. First, prioritize R&D investments in formulations that address unmet clinical needs-particularly adhesives engineered for minimally invasive delivery and for anatomies where conventional closure is challenging-while also considering modular portfolio strategies that balance biological and synthetic platforms. Second, enhance supply chain resilience through dual-sourcing of critical inputs, selective regional manufacturing capacity, and contractual clauses that provide flexibility in the event of trade or logistics disruption.

Third, accelerate clinical adoption by investing in high-quality, procedure-specific evidence and by designing training programs that reduce learning curves for surgeons and perioperative staff. Fourth, engage proactively with regulators and payers to shape pathways that recognize outcome-based benefits and to streamline reimbursement discussions. Fifth, adopt pricing and contracting models that reflect total cost of care benefits rather than unit price alone, which can unlock procurement dialogues in value-oriented health systems. Finally, pursue partnerships with device manufacturers, surgical platforms, and distribution networks to expand reach while preserving focus on core technological strengths. These steps collectively enable market leaders to translate scientific advantage into durable commercial outcomes.

A rigorous mixed-methods research framework combining clinician interviews, procurement insights, regulatory review, and triangulated secondary evidence to underpin conclusions and recommendations

This analysis integrates primary and secondary research methods to ensure evidence-based recommendations and rigorous validation of insights. Primary research comprised structured interviews with clinicians across specialties, procurement leaders in hospital systems and ambulatory surgical centers, manufacturing experts, and regulatory affairs professionals. These interviews informed qualitative understanding of adoption drivers, procedural workflows, and procurement sensitivities, and were supplemented by expert advisory sessions to validate interpretation and to stress-test strategic implications.

Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, product labeling and instructions for use, patent filings, and company disclosures to establish technical context and to confirm material science developments. Data synthesis applied triangulation techniques to reconcile differing inputs and to identify consistent themes across geographies and stakeholder groups. Throughout, emphasis was placed on transparency of assumptions, reproducibility of analytical approaches, and the separation of descriptive findings from strategic interpretation, enabling readers to trace the evidentiary basis for each recommendation and to adapt insights to their organizational context.

A concise synthesis of the strategic imperatives that will determine which surgical adhesive technologies achieve durable clinical adoption and commercial success

In summary, the surgical adhesives sector stands at an inflection point where materials innovation, procedural evolution, and commercial strategy must be tightly aligned to realize clinical and economic value. Adhesive technologies that respond to the technical demands of minimally invasive surgery, that offer reproducible performance in varied clinical settings, and that are supported by robust real-world evidence will be the most compelling to health systems focused on outcomes and efficiency. Concurrently, supply chain agility and thoughtful regional go-to-market approaches will differentiate companies able to ensure continuity of supply and to meet localized regulatory expectations.

As stakeholders navigate these dynamics, success will favor organizations that integrate scientific differentiation with disciplined operations, proactive regulatory engagement, and targeted clinical programs. By focusing on these priorities, industry participants can convert emerging opportunities into sustainable adoption and long-term partnership with the clinical community.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Development of bioresorbable polymer adhesives with controlled degradation rates for patient-specific surgical applications
• 5.2. Integration of antimicrobial and anti-inflammatory agents into surgical adhesives to reduce postoperative infection risk
• 5.3. Advancements in sprayable and aerosolized adhesives for minimally invasive and robotic surgery wound closure
• 5.4. Emergence of hybrid sealant adhesives combining hemostatic and bonding properties for complex cardiovascular procedures
• 5.5. Regulatory approvals accelerating pipeline for polyurethane-based adhesives in orthopedic and tissue engineering markets
• 5.6. Incorporation of nanotechnology and nanoparticles into surgical adhesives to enhance tissue adhesion strength and healing
• 5.7. Development of thermoresponsive adhesives that solidify at body temperature for precision laparoscopic and endoscopic surgeries
• 5.8. Focus on cost-effective single-use delivery systems for surgical adhesives to improve operating room workflow efficiency
• 5.9. Rising adoption of natural and plant-derived adhesives such as fibrin and chitosan for biocompatible wound sealing
• 5.10. Growth of customizable 3D printed adhesive scaffolds for personalized surgical reconstruction and wound management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Surgical Adhesives Market, by Product

• 8.1. Collagen-Based Adhesives
• 8.2. Cyanoacrylate Adhesives
• 8.3. Fibrin Sealants
• 8.4. Hydrocolloid Adhesives
• 8.5. Silicone Adhesives

9. Surgical Adhesives Market, by Composition

• 9.1. Biological Adhesives
• 9.2. Synthetic Adhesives

10. Surgical Adhesives Market, by Surgical Method

• 10.1. Minimally Invasive Surgery
• 10.2. Open Surgery

11. Surgical Adhesives Market, by Application

• 11.1. Cardiovascular Surgery
• 11.2. Cosmetic Surgery
• 11.3. General Surgery
• 11.4. Orthopedic Surgery

12. Surgical Adhesives Market, by End-User

• 12.1. Ambulatory Surgical Centers
• 12.2. Hospitals & Clinics
• 12.3. Specialty Care Centers

13. Surgical Adhesives Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Surgical Adhesives Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Surgical Adhesives Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. 3M Company
  • 16.3.2. Advanced Medical Solutions Group PLC
  • 16.3.3. Artivion, Inc
  • 16.3.4. B. Braun Melsungen AG
  • 16.3.5. Baxter International Inc.
  • 16.3.6. Becton, Dickinson, and Company
  • 16.3.7. Cardinal Health, Inc.
  • 16.3.8. Chemence Medical, Inc.
  • 16.3.9. Connexicon Medical Limited
  • 16.3.10. CSL Behring AG
  • 16.3.11. GEM S.r.l.
  • 16.3.12. GluStitch Inc.
  • 16.3.13. Grena Ltd.
  • 16.3.14. H.B. Fuller Company
  • 16.3.15. Henkel AG & Co. KGaA
  • 16.3.16. Integra LifeSciences Holdings Corporation
  • 16.3.17. Johnson & Johnson Services, Inc.
  • 16.3.18. Kuraray America, Inc.
  • 16.3.19. Medline Industries, LP
  • 16.3.20. Medtronic PLC
  • 16.3.21. Meyer-Haake GmbH Medical Innovations
  • 16.3.22. Mitsui Chemicals, Inc.
  • 16.3.23. Nordson Corporation
  • 16.3.24. Sealantis Ltd.
  • 16.3.25. UFP Technologies Inc.
  • 16.3.26. Vivostat A/S